Advanced Filters
noise

Cornebarrieu, France Clinical Trials

A listing of Cornebarrieu, France clinical trials actively recruiting patients volunteers.

Found 522 clinical trials

Identification of Human Biomarkers Predictive of Diabetes Remission in Type 2 Diabetes Patient (BARIAKINES)

This study focuses on identifying potentially predictive human circulating adipocyte and muscle biomarkers of diabetes remission after bariatric surgery in obese type 2 diabetic (T2D) subjects.

18 - 70 years of age All Phase N/A
M Mariella SPALATO CERUSO, MD

HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas

This trial is a two-step Phase I/II study comprising: Part 1: A dose escalation part with the aim to assess the safety of the proposed combination (N= up to 30 patients). In the dose escalation part, eligible patients will be treated with a fixed dose of pazopanib and escalating doses …

18 years of age All Phase 1/2
e elodie Ayem, ph

Music During Dental Children Care Under MEOPA

In France, the improvement of dental care for children in general and even more so for children with special needs is a real public health issue. Indeed, children under 6 years of age, children with a fear that is difficult to control and who have failed to receive care, or …

4 - 12 years of age All Phase N/A
M Marc-Olivier FISCHER, MD

Alveolar Recruitment Maneuvers, Intracerebral Hemodynamic and Oxygenation

This study aims to compare 2 alveolar recruitment maneuvers (ARM) in patients with cerebral injuries and acute respiratory distress syndrome (ARDS) in term of efficacy and tolerance.

18 years of age All Phase N/A
C Cécile McCambridge, MD, PhD

Can Connected Devices Increase the Success Rate of Benzodiazepine Withdrawals in the Elderly?

This is a prospective randomized open study, which aims to evaluate the benefit of a connected watch to help people aged 65 years and older to withdraw from BZD over a six-month period, compared with classical withdrawal (e.g without connected watch). The study will include 100 patients, 50 in the …

65 years of age All Phase N/A
G Gabrielle SELMES, MD

Impact of Neoadjuvant Hormonal Therapy on the Surgical Management of Extensive Ductal Carcinomas in Situ

Ductal carcinoma in situ (DCIS) accounts for approximately 20% of newly diagnosed breast cancer cases. Of these women, 20% require radical management in the form of mastectomy because of the extent of the lesions, which most often manifest as diffuse microcalcifications. This mutilating surgical management contrasts with the excellent prognosis …

40 years of age Female Phase 2
A Aude FLECHON, Doctor

TALazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced URothelial Carcinoma

The main objectif is to determine the efficacy of a maintenance treatment combining Talazoparib and Avelumab after platinum-based chemotherapy in patients with locally advanced/metastatic urothelial carcinoma.

18 years of age All Phase 2

ASPirin in Immune thRombocytopenia Patients With Cardiovascular disEase

The incidence of immune thrombocytopenia increases with older age. This population is at risk for arterial thrombosis. Due to an increased turn-over of platelets, low-dose aspirin once daily may be insufficient in this population to protect against arterial thrombosis. This study is aimed at assessing the pharmacodynamics of aspirin once …

18 years of age All Phase 2

FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study

The purpose of this trial is to assess dose related safety, efficacy, and pharmacokinetics (PK) of INT-787 in participants with severe alcohol-associated hepatitis (sAH).

18 - 65 years of age All Phase 2
G Gilles Freyer, MD

Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer

Randomized, open label, phase II multicenter study to assess the efficacy niraparib versus niraparib +bevacizumab maintenance in patients with newly diagnosed stage IIIA/B/C high-grade epithelial ovarian cancer with no residual disease after frontline surgery and treatment by adjuvant platinum-basedchemotherapy +/-bevacizumab.

18 - 99 years of age Female Phase 2

Simplify language using AI